Neuronal localization of fibroblast growth factor-9 immunoreactivity in human and rat brain

Fibroblast growth factor-9 (FGF-9) is a relatively new member of the FGF family isolated from the conditioned medium of a human glioblastoma cell line as a secreting-type factor that exhibits a growth-stimulating effect on cultured glial cells. In order to elucidate the roles of FGF-9 in the central nervous system, we investigated in detail the distribution of FGF-9 proteins in the normal human and rat brains by immunohistochemistry using two different antibodies specific to FGF-9. In both human and rat, a strong expression of FGF-9 immunoreactivity was localized mainly in neurons throughout the normal brain. Immunoreactive glial cells were rarely encountered. In the human brain, strong and uniform immunoreactivity was observed in neurons of cerebral cortex, hippocampus, substantia nigra, motor nuclei of the brainstem, and Purkinje cell layer. A detailed mapping in the rat brain showed a distribution of FGF-9 immunoreactivity in a widespread population of neurons, though the intensity varied between different locations and even among the same nucleus. The most prominent expression in rat was observed in neurons of the mitral cell layer of the olfactory bulb, red nucleus, mesencephalic trigeminal nucleus, motor trigeminal nucleus, facial nucleus, reticular nucleus and Purkinje cell layer. These findings suggest that FGF-9 plays an important role in the central nervous system and may have a potential function closely connected to neurons in the normal brain.     

Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes

Cytokines are involved in nerve regeneration by modulating the synthesis of neurotrophic factors. The role played by interleukin-6 (IL-6) in promoting nerve growth factor (NGF) after brain injury was investigated by monitoring the release of IL-6 and NGF in ventricular cerebrospinal fluid (CSF) of 22 patients with severe traumatic brain injuries. IL-6 was found in the CSF of all individuals and remained elevated for the whole study period. NGF appeared in the CSF if IL-6 levels reached high concentrations and was often detected simultaneously with or following an IL-6 peak. The amounts of NGF correlated with the severity of the injury, as indicated by the clinical outcome of the patients. The functional relationship of IL-6 and NGF was investigated utilizing cultured mouse astrocytes. The CSF of 8 patients containing IL-6 induced NGF production in astrocytes, whereas control CSF without IL-6 had no effect. The induction of NGF was inhibited up to 100% by adding anti-IL-6 antibodies. These results were corroborated when astrocytes were exposed to recombinant IL-6 at different concentrations resulting in NGF production. Thus, the production of IL-6 within the injured brain may likely contribute to the release of neurotrophic factors by astrocytes.     

Localization of basic fibroblast growth factor,a mitogen and angiogenic factor,in human brain tumors

Summary Fibroblast growth factor (FGF) is a potent angiogenic factor and a mitogen for a variety of mesoderm-and neuroectoderm-derived cell types (e.g., fibroblasts, endothelial cells, astrocytes, oligodendrocytes). After application of a monospecific polyclonal antiserum, we localized basic FGF on frozen sections of 73 human brain tumors using immunohisto-chemistry. FGF was present in a variable number of tumor cells (16/16 astrocytomas, 5/5 ependymomas, 0/3 benign and 4/7 anaplastic oligodendrogliomas, 11/12 glioblastomas, 11/11 meningiomas, 6/6 neurilemmomas, 0/3 pituitary adenomas, 2/2 choroid plexus papillomas, 0/1 neurocytoma, 2/2 benign fibrous histiocytomas, 2/5 metastatic carcinomas). FGF was detected in vascular cells of 59 tumors and in fibroblasts of connective tissue stroma from all papillomas and metastases. These results tend to indicate FGF involvement in the malignant progression of gliomas due to an autocrine or paracrine action. Histopathological aspects of malignant gliomas (e.g., pseudopalisading or pathological vessels) could be related to FGF activity.     

NGF和FGF对移植的兔5-HT、DA能性神经元的影响

本实验将含有5—HT和DA能性神经元的胎兔脑组织微块液用立体定向法移植至成年兔脑内。兔21只分为三组,每组7只:第一组加入NGF,第二组加FGF,第三组未加任何因子列为对照组。移植2个月后用高效液相色谱电化学法(HPLC-EC)测定移植神经元的递质(5-HT、DA)含量。结果显示1、2两组的5-HT和第二组DA含量均显著高于对照组(P<0.05,P<0.01)。因此,表明NGF和FGF可能具有促进移植神经元存活和分化的功能。     

Neuronatin mRNA in PC12 cells: downregulation by nerve growth factor

Neuronatin was recently cloned from neonatal rat brain (Biochem. Biophys. Res. Commun., 201 (1994) 1227–1234). In subsequent studies, we noted that neuronatin mRNA was brain-specific and that there were two alternatively spliced forms, α and β (Brain Res., 690 (1995) 92–98). Furthermore, on sequencing the human neuronatin gene, it was determined that the α-form was encoded by three exons, and the β-form was encoded by the first and third exons only (Genomics, 33 (1996) 292–297). The middle exon was spliced out in the β-form. The human neuronatin gene is located in single copy on chromosome 20q11.2-12 (Brain Res., 723 (1996) 8–22). These studies called for an understanding of the function of this gene. Therefore, we studied the expression of neuronatin in PC12 cells, an established model of neuronal growth and differentiation. Neuronatin mRNA expression was found to be abundant in undifferentiated PC12 cells. Treatment with nerve growth factor (NGF), resulting in neuronal differentiation, was associated with a downregulation of neuronatin mRNA expression. Removal of NGF was associated with a return of neuronatin mRNA levels towards baseline. These effects appear to be specific for NGF as they were not seen with transforming growth factor, epidermal growth factor, 12-O-tetradecanoylphorbol-13-acetate or dexamethasone. Although, basic fibroblast growth factor also reduced neuronatin mRNA levels, the effect was less pronounced than with NGF. The NGF-induced decrease in neuronatin mRNA occurred even in the presence of protein and RNA syntheses inhibitors. Of the two spliced forms, only the α-form was expressed in PC12 cells. In conclusion, we report the presence of neuronatin mRNA in PC12 cells, and that NGF downregulates its expression. These findings provide a basis for investigating the role of neuronatin in neuronal growth and differentiation.     

Nerve growth factor and injured peripheral nerve regeneration

Nerve growth factor （NGF） exhibits many biological activities, such as supply of nutrients, neuroprotection, and the generation and rehabilitation of injured nerves. The neuroprotective and neurotrophic qualities of NGF are generally recognized. NGF may enhance axonal regeneration and myelination of peripheral nerves, as well as cooperatively promote functional recovery of injured nerves and limbs. The clinical efficacy of NGF and its therapeutic potentials are reviewed here. This paper also reviews the latest NGF research developments for repairing injured peripheral nerve, thereby providing scientific evidence for the appropriate clinical application of NGF.     

Nerve growth factor effects on pyridine nucleotides after oxidant injury of rat pheochromocytoma cells

Neurotrophic factors regulate neuronal survival and neurite growth in development and following injury. Oxidative stress produced in neurons as a consequence of primary injury, or during reperfusion following ischemia, may contribute to cell death. Here, the effects of nerve growth factor (NGF) on the response to H2O2 injury were examined in the PC12 rat pheochromocytoma cell line. Specifically, the effect of NGF on cell viability after H2O2 injury was measured. Pretreatment with NGF enhanced survival after H2O2 treatment, as measured by Trypan blue dye exclusion, radiolabeled amino acid incorporation, tetrazolium salt reduction, or cytoplasmic enzyme release. One early event associated with H2O2 treatment was a rapid decrease in NAD+. Although initial decreases in NAD+ levels were similar in control and NGF-treated cells, the latter recovered more rapidly and extensively. The decline in total NAD observed after NGF treatment was almost equal in magnitude to the measured increase in NADP. Inhibition of poly(ADP-ribose) polymerase also enhanced viability following H2O2 injury. Treatment with both NGF and an inhibitor of this enzyme resulted in a greater reduction of H2O2 toxicity than was observed with either agent alone. These data suggest that NGF protection is multifactorial and that a significant component of the NGF effect is due to its regulatory role in the metabolism of pyridine nucleotides.     

Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds

Basic fibroblast growth factor (bFGF) is a polypeptide found within the CNS with potent effects on the survival and proliferation of CNS glia and endothelial cells, and on the survival and outgrowth of CNS neurons. Immunohistochemical methods were used to examine relative changes in the levels and distribution of bFGF following focal brain injury. Two monospecific antisera to bFGF were used to immunostain intact mature rat brain, and brain in which a focal mechanical lesion had been made in the dorsolateral cerebral cortex one week previously. In the intact brain, staining was localized primarily in neuronal cell bodies, especially in limbic structures. In injured brain, a marked increase of bFGF immunoreactivity was found at the borders of lesions, localized to the dense accumulation of cells, many of which resembled ‘reactive’ astroglia. Such increases in local bFGF concentrations may contribute to the cascade of cellular changes — including glial and capillary proliferation, and neural sprouting — that follows focal brain injury.     

Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia

Neurotrophic factors (NFs) play a pivotal role in the development of the central nervous system. They are thus also suspected of being involved in the etiology of schizophrenia. Previous studies reported a decreased level of serum brain-derived neurotrophic factor (BDNF) in schizophrenia, whereas the association of epidermal growth factor (EGF) with this illness remains controversial. Using a two-site enzyme immunoassay, we conducted the simultaneous measurement of serum BDNF and EGF levels in a group of patients with chronic schizophrenia (N = 74) and a group of normal controls matched in age, body mass index, smoking habit and sex (N = 87). We found that, compared to normal controls, patients with chronic schizophrenia exhibited lower serum levels of both BDNF and EGF across all ages examined (21–59 years). The serum levels of BDNF and EGF were negatively correlated in the controls (r = − 0.387, P = 0.0002) but not in the patients. Clinical parameters such as duration of illness and psychiatric rating scale also showed no robust correlations with the NF levels. Collectively, these results suggest that pervasive, abnormal signaling of NFs underlies the pathophysiology of chronic schizophrenia.     

Nerve growth factor receptor-mediated transport from cerebrospinal fluid to basal forebrain neurons

Recent data indicate that the neurons of the cholinergic basal forebrain (CBF) respond to nerve growth factor (NGF) with increased survival under experimental conditions and have NGF receptors which mediate the binding and retrograde transport of NGF from axon terminals to somata. Focal intraparenchymal injections of retrograde tracing agents into neuropil demonstrate that the distribution of axons from cholinergic nuclei to cortex and hippocampus is topographically restricted and largely ipsilateral. Monoclonal antibody 192, a well-characterized antibody which recognizes only the rat NGF receptor, was labelled with 125I and injected into a lateral ventricle of adult rats. Highly specific bilateral transport to numerous neurons of the CBF system was demonstrated by autoradiography. This result directly demonstrates that suitably targeted antibodies can be taken up by specific neuronal populations following intraventricular injection and implies that CBF neurons may be influenced by relatively high molecular weight substances injected into cerebrospinal fluid.     

Distribution of acidic fibroblast growth factor-like immunoreactivity in rat skeletal muscle fibers

Acidic fibroblast growth factor (aFGF) is a mitogenic, angiogenic and neurotrophic growth factor which promotes proliferation, but delays differentation of cultured myoblasts. Its mRNA is expressed in the skeletal muscle, however the distribution of aFGF in the postnatal skeletal muscle is poorly characterized. In the present study, the distribution of aFGF-like immunoreactivity (LI) was examined in developing and adult rat skeletal muscle fibers. In addition, the effect of the transection of the sciatic nerve on aFGF-LI in calf muscle fibers was examined. From the first postnatal day on, aFGF-immunoreactive (IR) muscle fibers were observed in different calf muscles. From the 7th postnatal day on a large number of muscle fibers exhibited aFGF-LI in the soleus muscle, some in plantaris and only few in gastrocnemius and extraocular muscles. Double-labelling with fast-myosin antibody showed that aFGF-LI was restricted to the slow oxidative muscle fibers. aFGF-IR intrafusal muscle fibers were seen in developing and mature muscle spindles. In addition, aFGF-IR nerve fibers and myoneural junctions were observed in different muscles. Transection of the sciatic nerve did not noticeably alter the expression pattern of aFGF-L[ in calf muscles during two-week period.The present study demonstrates aFGF-LI in the rat slow oxidative muscle fibers where it may have fiber-type specific functions in addition to its known trophic effects.     

Nerve growth factor (NGF) in cerebrospinal fluid (CSF) from patients with various neurological disorders

It has been recently shown that NGF is not only involved in the survival and development of sympathetic and neural crest-derived sensory neurons, but also in some mechanisms of the immune system. For this reason, we studied the content of NGF in CSF samples from patients with diseases in which neuroimmonological mechanisms seem to be involved (multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer disease, chronic relapsing polyradiculoneuritis, Guillain-Barré syndrome, and tumors of the nervous system), as well as from a number of normal control subjects. We setup an ELISA aimed at the beta subunit of NGF, obtaining good validation tests and a detection limit of 28 pg βNGF per ml. None of the samples was found to contain detectable levels of NGF and, when a concentration method for sample enrichment was used, only one patient was NGF-positive. This suggests that NGF is probably not involved in the neuroimmunological mechanisms underlying some inflammatory and degenerative diseases of the nervous system. Paper presented at the “International Quincke Symposium”, G?ttingen, September 18–21, 1991.     

CSF levels of a set of neurotrophic factors (brain-derived neurotrophic factor,nerve growth factor) and neuropeptides (neuropeptide Y,galanin) in epileptic children

This paper aims to investigate the possible roles of a set of neurotrophic factors (brain-derived neurotrophic factor-BDNF, nerve growth factor-NGF) and neuropeptides (neuropeptide Y-NPY, and galanin) in children with active epileptogenesis. The cerebrospinal fluid (CSF) levels of BDNF, NPY, NGF and galanin were measured with enzyme-linked immunosorbent assays in epileptic children (n = 73) and controls (n = 64). There were no significant alterations in the CSF levels of BDNF, NPY and NGF in epileptic children with active clinical seizures compared with the levels of controls. However profoundly depressed galanin levels were found in infants with epileptic encephalopathy (mean ± SD:0.63 ± 0.19 pg/ml) and significantly increased galanin levels were measured in children with drug resistant epilepsy during the period of status epilepticus (mean ± SD: 6.92 ± 1.19, pg/ml pg/ml) compared with the levels of controls. Depressed levels of galanin might reflect a defective anti-epileptogenic effect of galanin in infants with epileptic encephalopathy. On the contrary, increased CSF levels of galanin might be a result of anti-epileptogenic effects of this peptide in epileptic children with status epilepticus.     

Reactive astrogliosis after basic fibroblast growth factor (bFGF) injection in injured neonatal rat brain

Reactive gliosis was revealed by immunocytochemistry using antibodies against the glial fibrillary acidic protein (GFAP) after a stab or an electrolytic lesion administered to the cerebral cortex, corpus callosum, striatum, or hippocampus of a 6-day-old rat. The intensity of the gliosis was about the same in the various structures injured and did not change with the delay of 3, 7, or 20 days between the injury and the sacrifice of the animals. When basic fibroblast growth factor (bFGF) was injected in the lesion locus just after the lesion was performed, it resulted (as soon as 3 days after injury) in a strong astrogliosis that was enhanced after a delay of 7 days, the astrocytes in the lesion area exhibiting enlarged cell processes and intense GFAP-positive immunoreactivity. After a delay of 20 days, the astrocytes were not dispersed any more but packed in three or four layers along the borders of the lesion, thus reducing its extension. This suggests a possible role for bFGF in promoting scar formation following brain injury.     

Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments

Nerve growth factor (NGF) and choline acetyltransferase (ChAT) activity levels were measured in 7 different brain regions in young (3-month-old) and aged (2-years-old) female Sprague-Dawley rats. Prior to analysis the spatial learning ability of the aged rats was assessed in the Morris' water maze test. In the aged rats a significant, 15–30%, increase in NGF levels was observed in 4 regions (septum, cortex, olfactory bulb and cerebellum), whereas the levels in hippocampus, striatum and the brainstem were similar to those of the young rats. The NGF changes did not correlate with the behavioral performance within the aged group. Minor 15–30%, changes in ChAT activity were observed in striatum, brainstem and cerebellum, but these changes did not correlate with the changes in NGF levels in any region. The results indicate that brain NGF levels are maintained at a normal or supranormal levels in rats with severe learning and memory impairments. Ther results, therefore, do not support the view that the marked atrophy and cell loss in the forebrain cholinergic system that is known to occur in the behaviorally impaired aged rats is caused by a reduced availability of NGF in the cholinergic target areas. The results also indicate that the slightly increased levels of NGF are not sufficient to prevent the age-dependent atrophy of cholinergic neurons, although they might be important for the stimulation of compensatory functional changes in a situation where the system is undergoing progressive degeneration.     

依达拉奉联合神经生长因子治疗重型颅脑损伤的疗效分析

目的 探讨依达拉奉联合神经生长因子治疗重型颅脑损伤的疗效。方法 2014年1月至2016年6月收治符合标准的重型颅脑损伤90例,根据治疗方法分为对照组和观察组,各45例。对照组给予常规治疗,观察组在对照组的基础上加用依达拉奉联合神经生长因子;疗程2周。治疗前、治疗后2周采用酶联免疫吸附法测定血清髓鞘碱性蛋白（MBP）、神经元特异性烯醇化酶（NSE）、S100β、白细胞介素-6（IL-6）和超敏C反应蛋白（CRP）水平;采用Image-Pro Plus软件计算CT影像脑水肿面积;治疗后3个月采用GOS评分评估预后。结果 治疗后2周,两组血清IL-6、S100β、MBP、NSE和hs-CRP水平均明显下降（P<0.05）,但观察组下降幅度更明显（P<0.05）。治疗后2周,两组脑水肿面积和APACHE-Ⅱ评分均明显下降（P<0.05）,GCS评分明显上升（P<0.05）,观察组的变化幅度更明显（P<0.05）。治疗后3个月,观察组预后良好率（64.44%,29/45;GOS评分4~5分）明显高于对照组（46.67,1/45;P<0.05）。结论 依达拉奉联合鼠神经生长因子可以保护重症颅脑损伤患者的神经功能因子,降低脑水肿面积,缓解炎症,促进患者意识恢复。     

Previously reported nerve growth factor levels are underestimated due to an incomplete release from receptors and interaction with standard curve media

The 1996 research report by Hoener et al. [M.C. Hoener, E. Hewitt, J. M. Conner, J.W. Costello, S. Varon, Nerve growth factor (NGF) content in adult rat brain tissue is several-fold higher than generally reported and is largely associated with sedimentable fractions, Brain Res. 728 (1996) 47-56.] compares levels of nerve growth factor (NGF) found in rat brain by assaying both supernatant and pellet to previously reported data. However, Hoener et al. miscalculated when converting values previously reported in the literature to units of picogram per milliliter. Regardless of this mistake, the method of tissue extraction does affect the extent of release of NGF, which must be maximized in order to accurately determine NGF levels in the central nervous system. We now report that accurate measurement of NGF levels is not only affected by the incomplete release of NGF from receptors, but also the medium in which the standard curve is run. It is the combination of these two variables that has led to the underestimation of NGF levels in previous research.     

Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and is largely associated with sedimentable fractions

Initial studies had revealed that the bioactivity of nerve growth factor (NGF) in sonicates of adult rat hippocampal formation (HF) is several-fold greater in their pellet than their supernatant fractions. Such observations have prompted an analysis of NGF antigen (NGF-Ag) contents in pellets and supernatants from a variety of adult rat CNS tissues, both in the absence and the presence of exogenous β-NGF. With HF tissues, NGF-Ag in the supernatants was comparable to most literature values, but pellet NGF-Ag was 3 to 5 times that amount. All other CNS tissue sonicates also revealed 3–6 fold higher NGF-Ag in their pellets than their supernatants, hence overall NGF-Ag contents were greatly in excess of reported ones. Presentation of mouse β-NGF to a tissue, its sonicate, or its standard pellet resulted in a transfer to the final pellet of 30–50% of the added soluble NGF-Ag (and 30% of the added bioactivity). This percentage is much lower than that present in native pellets (80%), suggesting that the association of endogenous NGF with particulate matter may involve at least two compartments. Treatments of pellets with salt, alkaline pH, and/or the detergent Triton X-100 have revealed a third subset, namely additional pellet NGF-Ag that was not initially recognized by the antibody in our ELISA assay. The treatments also caused substantial release of NGF from pellet to supernatant. Further studies should clarify the nature of the association between NGF and the three subsets of pellet NGF and allow the investigation of the pellet molecules responsible for it.     

Changes in cerebrospinal fluid nerve growth factor levels during chick embryonic development

In the early stages of brain development, cells within the ependymal lining of the neural tube are thought to secrete cerebrospinal fluid (CSF), the so-called neural tube fluid (NTF), whereas before fusion of the neural folds, the neuroepithelium that lines the inside of the neural tube is in contact with amniotic fluid. As the neural tube closes, a membrane formed from these cells invaginates to form the specialized choroid plexus. The choroid plexus is a highly vascularized epithelial cell structure that secretes proteins, including growth factors, into the CSF. Embryonic CSF (e-CSF) contains high concentrations of proteins compared to adult CSF. CSF has been reported to contain nerve growth factor (NGF) and other neurotrophic factors. In this study, total protein concentration and NGF level in e-CSF samples from chick embryos were measured using a dye-based protein assay, enzyme-linked immunosorbent assay (ELISA) and Western blot. The total protein concentration and NGF levels in the CSF decreased from days E10 to E16. There was a rapid increase in total protein content on days E17 and E18, and thereafter the levels decreased from day E19 to day E21. Days E17 and E18 coincide with the onset of neuron migration, proliferation and organization of the cytoarchitecture of the developing cerebral cortex. After that time the total protein concentration and NGF levels decrease until hatching. Since CSF is in contact with the cerebral cortical germinal epithelium, changes in the protein concentration in the CSF could affect neuroepithelial cell proliferation, survival and migration. It is concluded that NGF is not only a constant component of CSF during chick embryogenesis but it might also be involved in cerebral cortical development.